{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Inoue Y"],"funding":["Japanese Society of Hematology","Research Clusters program of Tokushima University","Bristol Myers Squibb Foundation","Japan Society for the Promotion of Science"],"pagination":["559-563"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11786308"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["116(2)"],"pubmed_abstract":["Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1-like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL-2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody-dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti-SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7-expressing MM cell lines an"],"journal":["Cancer science"],"pubmed_title":["Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction."],"pmcid":["PMC11786308"],"funding_grant_id":["21H03111","JP23H03101","JP17H05104","23195","2202003","22K19626","JP22K08455","JP19K22719"],"pubmed_authors":["Hiasa M","Maeda Y","Kagawa K","Ozaki S","Oda A","Endo I","Harada T","Maruhashi T","Fujii S","Abe M","Hara T","Oura M","Sumitani R","Sogabe K","Teramachi J","Takahashi M","Miki H","Inoue Y","Nakamura S","Tenshin H"],"additional_accession":[]},"is_claimable":false,"name":"Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.","description":"Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1-like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL-2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody-dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti-SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7-expressing MM cell lines an","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-03T23:41:52.081Z","creation":"2025-04-03T23:41:52.081Z"},"accession":"S-EPMC11786308","cross_references":{"pubmed":["39557586"],"doi":["10.1111/cas.16401"]}}